WFNOS 2017
Clinical trials of VAL-083 in patients with chemoresistant glioblastoma
Clinical trials of VAL-083 in patients with chemoresistant glioblastoma
Distinct mechanism of action of dianhydrogalactitol (VAL-083) overcomes chemoresistance in glioblastoma
Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Overcoming Chemoresistance in Glioblastoma
DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells
Assessment of Dianhydrogalactitol (VAL-083) in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemo-resistance
Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemo-resistance
Clinical Trials of VAL-083 in Patients with Chemo-Resistant Glioblastoma
Assessment of dianhydrogalactitol (VAL-083) in the treatment of relapsed or refractory non-small cell lung cancer (NSCLC)
Dianhydrogalactitol (VAL-083) causes irreparable DNA double-strand breaks, S/G2 phase cell-cycle arrest and tumor cell death in an MGMT independent manner offering a unique treatment paradigm for GBM